|
Product
|
IL-27 Antibody
|
|
Cat#
|
100-12-20A
|
|
Unit/Weight
|
100 μg
|
|
Unit Price
|
$266.00
|
|
Species Reactivity
|
H, M
|
|
Tested Application(s)
|
E, WB
|
|
Brief Description
|
(IN) Interleukin 27 induce tumor-specific anti-tumor activity mediated through CD8+ T-cells, IFN-gamma, and T-bet.
|
|
Specific Description
|
Like interleukin-23 (IL-23), IL-27 is a recently discovered member of the IL-6/IL-12 family of proinflammatory and immunoregulatory cytokines. It exists as a heterodimer composed of the p40-related protein EBI3 and an IL-12 p35-related protein termed p28. IL-27 is produced after activation by antigen-presenting cells and induces proliferation of na飗e but not memory CD4+ T-cells. It acts by binding to its receptor WSX-1 and gp130 which results in the activation of a Jak/STAT signaling cascade, suggesting the IL-27 is involved in the regulation of immune processes. It has been suggested that IL-27 can also be used as a therapeutic agent against cancer as it can also induce tumor-specific anti-tumor activity mediated through CD8+ T-cells, IFN-gamma, and T-bet.
|
|
Storage
|
IL-27 antibody can be stored at 4°C, stable for one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
|
|